title: High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma.
abstract: We surveyed IL-21 receptor (IL-21R) in leukemia and lymphoma and found that follicular lymphoma cells showed exceptionally high IL-21R expression. Notably, IL-21 showed divergent effects depending on the cell origin: growth stimulation in Burkitt lymphoma cell lines and adult T cell leukemia/lymphoma cell lines but induction of apoptosis in B lymphoma cell lines with t(14;18)(q32;q21), a marker karyotype of follicular lymphoma. IL-21 activated caspase-8 and -3 and reduced mitochondrial membrane potential. More importantly, IL-21 decreased Bcl-2 expression but increased Bax expression. These results support a new therapeutic approach using the IL-21/IL-21R system in follicular lymphoma.
authors.affiliation: Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
authors.forename: Norihiko
authors.initials: N
authors.lastname: Akamatsu
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Yamada
authors.forename: Hiroo
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Koki
authors.initials: K
authors.lastname: Makabe
authors.forename: Ryutaro
authors.initials: R
authors.lastname: Asano
authors.forename: Izumi
authors.initials: I
authors.lastname: Kumagai
authors.forename: Ken
authors.initials: K
authors.lastname: Murata
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Imaizumi
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Tsukasaki
authors.forename: Kazuto
authors.initials: K
authors.lastname: Tsuruda
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Sugahara
authors.forename: Sunao
authors.initials: S
authors.lastname: Atogami
authors.forename: Katsunori
authors.initials: K
authors.lastname: Yanagihara
authors.forename: Shimeru
authors.initials: S
authors.lastname: Kamihira
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D053181:Caspase 8 / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D006801:Humans; D007378:Interleukins / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D019169:Jurkat Cells; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D053078:Membrane Potential, Mitochondrial; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D053655:Receptors, Interleukin-21 / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013997:Time Factors; D014407:Tumor Cells, Cultured; D020298:U937 Cells; D051028:bcl-2-Associated X Protein / Q000378:metabolism; D000098546:Interleukin-21
chemical_list: D000970:Antineoplastic Agents; D007378:Interleukins; D019253:Proto-Oncogene Proteins c-bcl-2; D053655:Receptors, Interleukin-21; D011994:Recombinant Proteins; D051028:bcl-2-Associated X Protein; D053148:Caspase 3; D053181:Caspase 8; D000098546:Interleukin-21